Effect of Insulin on Airway Responsiveness in Patients with Type 2 Diabetes Mellitus: A Cohort Study
Authors:
- Claudio TerzanoCTClaudio Terzano
- Susanna MoranoSMSusanna Morano
- Daniela CeccarelliDCDaniela Ceccarelli
- Vittoria ContiVCVittoria Conti
- Gregorino PaoneGPGregorino Paone
- Angelo PetroianniAPAngelo Petroianni
- Elda GrazianiEGElda Graziani
- Anna CarnovaleACAnna Carnovale
- Mara FallarinoMFMara Fallarino
- Alessandra GattiAGAlessandra Gatti
- Elisabetta MandosiEMElisabetta Mandosi
- Andrea LenziALAndrea Lenzi
- 1 January 2009
- journal article
- clinical trial
- Published by Taylor & Francis in Journal of Asthma
- Vol. 46 (7) , 703-707
Abstract
BACKGROUND: The correlation between low insulin levels and a decreased sensitivity of the muscarinic receptor has been shown on induced-diabetes animal models. We designed a cohort study with the aim of evaluating the effects of insulin therapy on airway responsiveness (AR) in human patients with type 2 diabetes mellitus. METHODS: We enrolled 92 patients with type 2 diabetes who had switched from oral anti-diabetic therapy to treatment by insulin subcutaneous injection. Patients were administered the methacholine challenge test (MCT) at time 0 (pre-insulin therapy) and at intervals of 15, 30, 90, 180, and 360 days after insulin treatment. The decline of forced expiratory volume in 1 second (FEV(1))% from baseline (Delta FEV(1)) in response to inhaled methacholine (MCH) was determined to assess airway hyper-responsiveness (AHR). RESULTS: A total of 81 patients (18 women and 63 men) completed the study. Their mean age was 58 +/- 7 years and the mean duration of disease was 13.5 +/- 7.7 years. The mean decrease of FEV(1) at pre-insulin assessment was 2.96 +/- 2.6%. Compared with the pre-insulin value, a significant increase of Delta FEV(1) was observed at 15, 30, and 90 days after treatment (6.25%, CI 95% 5.4 to 7.2, p = 0.0005; 7.64%, CI 95% 6.6 to 8.1, p < 0.001; 6.45%, CI 95% 5.5 to 7.3, p = 0.0004, respectively), while after 180 and 360 days AR was similar to pre-insulin values (Delta FEV(1), 3.62%, CI 95% 2.7 to 3.5 and 3.11%, CI 95% 7.9 to 9.3, respectively). CONCLUSIONS: The finding of an increased AR in patients with type 2 diabetes during the first 3 months of insulin therapy may underline the importance of monitoring pulmonary function and respiratory symptoms in patients switching from oral anti-diabetic drugs to insulin therapy, especially in the subset of individuals with respiratory disordersKeywords
This publication has 30 references indexed in Scilit:
- Evaluation of Glucose Tolerance Status in Patients with Asthma BronchialeJournal of Asthma, 2009
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2007
- Long-term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetesInternational Journal Of Clinical Practice, 2007
- Interleukin 13 and the β-adrenergic blockade theory of asthma revisited 40 years laterAnnals of Allergy, Asthma & Immunology, 2007
- Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 DiabetesDiabetes Care, 2007
- Insulin induces airway smooth muscle contractionBritish Journal of Pharmacology, 2007
- Increased function of inhibitory neuronal M2 muscarinic receptors in trachea and ileum of diabetic ratsBritish Journal of Pharmacology, 2002
- Increased function of inhibitory neuronal M2 muscarinic receptors in diabetic rat lungsBritish Journal of Pharmacology, 1997
- Juvenile Diabetes Mellitus and AtopyHuman Heredity, 1971
- The beta adrenergic theory of the atopic abnormality in bronchial asthmaJournal of Allergy, 1968